The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4474-4483

  Sharma, Arun K ^a   Kline, Christina L ^a   Berg, Arthur ^a   Amin, Shantu ^a   Irby, Rosalyn B ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; GLUCOSE REGULATED PROTEIN 78; ONCOPROTEIN; PHENYLBUTYL ISOSELENOCYANATE 4; PROSTATE APOPTOSIS RESPONSE PROTEIN 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BYSTANDER EFFECT; CELL DEATH; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; MICE; MICE, NUDE; ORGANOSELENIUM COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 79960335679     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2370     Document Type: Article

References (52)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA. Cancer J Clin 60:277-300.
2. Boehrer S, Nowak D, E EP, Ruthardt M, Sattler N, Trepohl B, et al. Prostate-apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis. Leuk Res 2006;30:597-605. (Pubitemid 43374589)
3. Cook J, Krishnan S, Ananth S, Sells SF, Shi Y, Walther MM, et al. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 1999;18:1205-8. (Pubitemid 29085993)
4. Sells SF, Han SS, Muthukkumar S, Maddiwar N, Johnstone R, Boghaert E, et al. Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol 1997;17:3823-32. (Pubitemid 27281857)
5. Barradas M, Monjas A, Diaz-Meco MT, Serrano M, Moscat J. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression.EMBO J 1999;18:6362-9.
6. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, Tendero MJ, Rodriguez-Pinilla SM, Garcia-Cao I, et al. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 2007;67:1927-34. (Pubitemid 46424208)
7. Qiu SG, Krishnan S, el-Guendy N, Rangnekar VM. Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation. Oncogene 1999;18:7115-23.
8. Joshi J, Fernandez-Marcos PJ, Galvez A, Amanchy R, Linares JF, Duran A, et al. Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J 2008;27:2181-93.
9. Wang BD, Kline CL, Pastor DM, Olson TL, Frank B, Luu T, et al. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Mol Cancer 2010;9:98.
10. Goswami A, Burikhanov R, de Thonel A, Fujita N, Goswami M, Zhao Y, et al. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell 2005;20:33-44. (Pubitemid 41396560)
11. Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 2005;25:1146-61. (Pubitemid 40165820)
12. Lee JW, Lee KF, Hsu HY, Hsu LP, Shih WL, Chu YC, et al. Protein expression and intracellular localization of prostate apoptosis response-4 (Par-4) are associated with apoptosis induction in nasopharyngeal carcinoma cell lines. Cancer Lett 2007;257:252-62.
13. Boehrer S, Chow K, Beske F, Kukoc-Zivojnov N, Puccetti E, Ruthardt M, et al. In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res 2002;62:1768-75.
14. Ahmed MM, Sheldon D, Fruitwala MA, Venkatasubbarao K, Lee EY, Gupta S, et al. Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. Int J Cancer 2008; 122:63-70. (Pubitemid 350209979)
15. Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 2009;138:377-88.
16. Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 2001;61:7255-63. (Pubitemid 32946523)
17. Bergmann M, Kukoc-Zivojnov N, Chow KU, Trepohl B, Hoelzer D, Weidmann E, et al. Prostate apoptosis response gene-4 sensitizes neoplastic lymphocytes to CD95-induced apoptosis. Ann Hematol 2004;83:646-53. (Pubitemid 39317489)
18. Goswami A, Ranganathan P, Rangnekar V. The Phosphoinositide 3-Kinase/Akt1/Par-4 Axis: A Cancer-Selective Therapeutic Target. Cancer Res 2006;66:2889-92.
19. Kwon KH, Barve A, Yu S, Huang MT, Kong AN. Cancer chemoprevention by phytochemicals: potential molecular targets, biomarkers and animal models. Acta Pharmacol Sin 2007;28:1409-21. (Pubitemid 47366691)
20. Sporn MB, Liby KT. Cancer chemoprevention: scientific promise, clinical uncertainty. Nat Clin Pract Oncol 2005;2:518-25. (Pubitemid 41553936)
21. Zhang X, Jin B, Huang C. The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. Curr Cancer Drug Targets 2007;7:305-16. (Pubitemid 46849235)
22. Kada F, Saji M, Ringel MD. Akt: a potential target for thyroid cancer therapy. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:181-5. (Pubitemid 39199356)
23. Moser AR, Luongo C, Gould KA, McNeley MK, Shoemaker AR, Dove WF. ApcMin: a mouse model for intestinal and mammary tumorigenesis. Eur J Cancer 1995;31A:1061-4.
24. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63. (Pubitemid 41079915)
25. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002;23:201-5. (Pubitemid 34213570)
26. Shtilbans V, Wu M, Burstein DE. Current overview of the role of Akt in cancer studies via applied immunohistochemistry. Ann Diagn Pathol 2008;12:153-60. (Pubitemid 351312912)
27. Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, et al. Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin Cancer Res 2009;15:1674-85.
28. Sharma AK, Sharma A, Desai D, Madhunapantula SV, Huh SJ, Robertson GP, et al. Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. J Med Chem 2008;51:7820-6.
29. Chung FL, Jiao D, Conaway CC, Smith TJ, Yang CS, Yu MC. Chemopreventive potential of thiol conjugates of isothiocyanates for lung cancer and a urinary biomarker of dietary isothiocyanates. J Cell Biochem Suppl 1997;27:76-85. (Pubitemid 28222122)
30. Stoner GD, Adams C, Kresty LA, Amin SG, Desai D, Hecht SS, et al. Inhibition of N'-nitrosonornicotine-induced esophageal tumorigenesis by 3-phenylpropyl isothiocyanate. Carcinogenesis 1998;19: 2139-43. (Pubitemid 29010253)
31. Traka M, Mithen R. Glucosinolates, isothiocyanates and human health. Phytochem Rev 2009;8:269-82.
32. Beecher CW. Cancer preventive properties of varieties of Brassica oleracea: a review. Am J Clin Nutr 1994;59:1166S-70S.
33. Chung KY, Saltz LB. Adjuvant therapy of colon cancer: current status and future directions. Cancer J 2007;13:192-7.
34. Conaway CC, Getahun SM, Liebes LL, Pusateri DJ, Topham DK, Botero-Omary M, et al. Disposition of glucosinolates and sulforaphane in humans after ingestion of steamed and fresh broccoli. Nutr Cancer 2000;38:168-78. (Pubitemid 32762016)
35. Talalay P, Fahey JW. Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. J Nutr 2001;131:3027S-33S.
36. Yu R, Mandlekar S, Harvey KJ, Ucker DS, Kong AN. Chemopreventive isothiocyanates induce apoptosis and caspase-3-like protease activity. Cancer Res 1998;58:402-8. (Pubitemid 28087397)
37. Zhang Y, Talalay P. Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. Cancer Res 1994;54: 1976s-81s.
38. Reddy BS, Wynn TT, el-Bayoumy K, Upadhyaya P, Fiala E, Rao CV. Evaluation of organoselenium compounds for potential chemopreventive properties in colon cancer. Anticancer Res 1996;16: 1123-7.
39. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276: 1957-63.
40. Combs GF Jr, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther 1998;79:179-92. (Pubitemid 28393874)
41. El-Bayoumy K. The role of selenium in cancer prevention. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology, 4th ed. Philadelphia, PA: JB Lippincott; 1991. p.1-15.
42. Jacobs ET, Jiang R, Alberts DS, Greenberg ER, Gunter EW, Karagas MR, et al. Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst 2004;96:1669-75. (Pubitemid 39591588)
43. Mikac-Devic M, Vukelic N, Kljaic K. Serum selenium level in patients with colorectal cancer. Biol Trace Elem Res 1992;33:87-94.
44. Milde D, Novak O, Stu ka V, Vyslou il K, Macha ek J. Serum levels of selenium, manganese, copper, and iron in colorectal cancer patients. Biol Trace Elem Res 2001;79:107-14.
45. Wang BD, Kline CL, Pastor DM, Olson TL, Frank B, Luu T, et al. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NFkappaB and microRNA network. Mol Cancer 2010;9:98.
46. Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P. Sequence-dependent activity of the irinotecan-5FU combination in human coloncancer model HT-29 in vitro and in vivo. Int J Cancer 1997;73:729-34. (Pubitemid 127483072)
47. Ritz C, Streibig JC. Bioassay analysis using R. J Statist Software 2005;12:1-22. (Pubitemid 40218001)
48. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
49. Kline CL, Shanmugavelandy SS, Kester M, Irby RB. Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biol Ther 2009;8:1831-7.
50. Misra UK, Gonzalez-Gronow M, Gawdi G, Hart JP, Johnson CE, Pizzo SV. The role of Grp 78 in alpha 2-macroglobulin-induced signal transduction. Evidence from RNA interference that the low density lipoprotein receptor-related protein is associated with, but not necessary for, GRP 78-mediated signal transduction. J Biol Chem 2002;277:42082-7. (Pubitemid 35257523)
51. Monga DK, O'Connell MJ. Surgical adjuvant therapy for colorectal cancer: current approaches and future directions. Ann Surg Oncol 2006;13:1021-34. (Pubitemid 44337961)
52. Matsuyama R, Togo S, Shimizu D, Momiyama N, Ishikawa T, Ichikawa Y, et al. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int J Cancer 2006;119: 406-13.